Mucoadhesive Hybrid System of Silk Fibroin Nanoparticles and Thermosensitive In Situ Hydrogel for Amphotericin B Delivery: A Potential Option for Fungal Keratitis Treatment

Overview

Journal Polymers (Basel)

Publisher MDPI

Date 2024 Jan 11

PMID 38201813

Authors

Pratthana Chomchalao

Nuttawut Saelim

Supaporn Lamlertthon

Premnapa Sisopa

Waree Tiyaboonchai

Affiliations

Soon will be listed here.

Abstract

The purpose of this work was to investigate the feasibility of a novel ophthalmic formulation of amphotericin B-encapsulated silk fibroin nanoparticles incorporated in situ hydrogel (AmB-FNPs ISG) for fungal keratitis (FK) treatment. AmB-FNPs ISG composites were successfully developed and have shown optimized physicochemical properties for ocular drug delivery. Antifungal effects against and in vitro ocular irritation using corneal epithelial cells were performed to evaluate the efficacy and safety of the composite formulations. The combined system of AmB-FNPs-ISG exhibited effective antifungal activity and showed significantly less toxicity to HCE cells than commercial AmB. In vitro and ex vivo mucoadhesive tests demonstrated that the combination of silk fibroin nanoparticles with in situ hydrogels could enhance the adhesion ability of the particles on the ocular surface for more than 6 h, which would increase the ocular retention time of AmB and reduce the frequency of administration during the treatment. In addition, AmB-FNP-PEG ISG showed good physical and chemical stability under storage condition for 90 days. These findings indicate that AmB-FNP-PEG ISG has a great potential and be used in mucoadhesive AmB eye drops for FK treatment.

Citing Articles

Development of sustained-release extemporaneous moxifloxacin loaded commercial soft hydrogel contact lenses.

Pham D, Chomchalao P, Bunneramit K, Kladcharoen P, Khotcharrat R, Tiyaboonchai W Heliyon. 2025; 11(3):e42436.

PMID: 39991249 PMC: 11847108. DOI: 10.1016/j.heliyon.2025.e42436.

Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment.

Yan K, Zhang Q, Liu Q, Han Y, Liu Z Theranostics. 2025; 15(3):915-942.

PMID: 39776812 PMC: 11700875. DOI: 10.7150/thno.103266.

Development of pH-responsive Eudragit S100-functionalized silk fibroin nanoparticles as a prospective drug delivery system.

Pham D, Nguyen D, Nguyen N, Nguyen T, Nguyen T, Tu A PLoS One. 2024; 19(5):e0303177.

PMID: 38781182 PMC: 11115272. DOI: 10.1371/journal.pone.0303177.

References

Adhikari K, Buatong W, Thawithong E, Suwandecha T, Srichana T . Factors Affecting Enhanced Permeation of Amphotericin B Across Cell Membranes and Safety of Formulation. AAPS PharmSciTech. 2015; 17(4):820-8. DOI: 10.1208/s12249-015-0406-x. View

Dannert C, Stokke B, Dias R . Nanoparticle-Hydrogel Composites: From Molecular Interactions to Macroscopic Behavior. Polymers (Basel). 2019; 11(2). PMC: 6419045. DOI: 10.3390/polym11020275. View

Albadr A, Tekko I, Vora L, Ali A, Laverty G, Donnelly R . Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections. Drug Deliv Transl Res. 2021; 12(4):931-943. PMC: 8888497. DOI: 10.1007/s13346-021-01032-2. View

Almeida H, Amaral M, Lobao P, Silva A, Loboa J . Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. J Pharm Pharm Sci. 2014; 17(3):278-93. DOI: 10.18433/j3dp43. View

Petrillo F, Sinoca M, Fea A, Galdiero M, Maione A, Galdiero E . Candida Biofilm Eye Infection: Main Aspects and Advance in Novel Agents as Potential Source of Treatment. Antibiotics (Basel). 2023; 12(8). PMC: 10451181. DOI: 10.3390/antibiotics12081277. View

Chennell P, Yessaad M, Abd El Kader F, Jouannet M, Wasiak M, Bouattour Y . Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl-γ-Cyclodextrins Possess an Extended Physicochemical Stability?. Pharmaceutics. 2020; 12(9). PMC: 7559369. DOI: 10.3390/pharmaceutics12090786. View

Bachu R, Chowdhury P, Al-Saedi Z, Karla P, Boddu S . Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases. Pharmaceutics. 2018; 10(1). PMC: 5874841. DOI: 10.3390/pharmaceutics10010028. View

Fu T, Yi J, Lv S, Zhang B . Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. J Liposome Res. 2016; 27(3):228-233. DOI: 10.1080/08982104.2016.1224899. View

Sun R, Jones D, Wilhelmus K . Clinical characteristics and outcome of Candida keratitis. Am J Ophthalmol. 2007; 143(6):1043-1045. PMC: 2040331. DOI: 10.1016/j.ajo.2007.02.016. View

10.

Bubonja-Sonje M, Knezevic S, Abram M . Challenges to antimicrobial susceptibility testing of plant-derived polyphenolic compounds. Arh Hig Rada Toksikol. 2021; 71(4):300-311. PMC: 7968511. DOI: 10.2478/aiht-2020-71-3396. View

11.

Huang J, Zhong J, Chen G, Lin Z, Deng Y, Liu Y . A Hydrogel-Based Hybrid Theranostic Contact Lens for Fungal Keratitis. ACS Nano. 2016; 10(7):6464-73. DOI: 10.1021/acsnano.6b00601. View

12.

Jumelle C, Gholizadeh S, Annabi N, Dana R . Advances and limitations of drug delivery systems formulated as eye drops. J Control Release. 2020; 321:1-22. PMC: 7170772. DOI: 10.1016/j.jconrel.2020.01.057. View

13.

Elhabal S, Ghaffar S, Hager R, Elzohairy N, Khalifa M, Mohie P . Development of thermosensitive hydrogel of Amphotericin-B and Lactoferrin combination-loaded PLGA-PEG-PEI nanoparticles for potential eradication of ocular fungal infections: , and studies. Int J Pharm X. 2023; 5:100174. PMC: 9992749. DOI: 10.1016/j.ijpx.2023.100174. View

14.

Pham D, Saelim N, Cornu R, Beduneau A, Tiyaboonchai W . Crosslinked Fibroin Nanoparticles: Investigations on Biostability, Cytotoxicity, and Cellular Internalization. Pharmaceuticals (Basel). 2020; 13(5). PMC: 7281390. DOI: 10.3390/ph13050086. View

15.

Patel A, Cholkar K, Agrahari V, Mitra A . Ocular drug delivery systems: An overview. World J Pharmacol. 2015; 2(2):47-64. PMC: 4289909. DOI: 10.5497/wjp.v2.i2.47. View

16.

Chhonker Y, Durga Prasad Y, Chandasana H, Vishvkarma A, Mitra K, Shukla P . Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol. 2014; 72:1451-8. DOI: 10.1016/j.ijbiomac.2014.10.014. View

17.

Shaikh R, Raghu Raj Singh T, Garland M, Woolfson A, Donnelly R . Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011; 3(1):89-100. PMC: 3053525. DOI: 10.4103/0975-7406.76478. View

18.

Grassiri B, Zambito Y, Bernkop-Schnurch A . Strategies to prolong the residence time of drug delivery systems on ocular surface. Adv Colloid Interface Sci. 2021; 288:102342. DOI: 10.1016/j.cis.2020.102342. View

19.

Takahashi Y, Koike M, Honda H, Ito Y, Sakaguchi H, Suzuki H . Development of the short time exposure (STE) test: an in vitro eye irritation test using SIRC cells. Toxicol In Vitro. 2008; 22(3):760-70. DOI: 10.1016/j.tiv.2007.11.018. View

20.

Atta S, Perera C, Kowalski R, Jhanji V . Fungal Keratitis: Clinical Features, Risk Factors, Treatment, and Outcomes. J Fungi (Basel). 2022; 8(9). PMC: 9504427. DOI: 10.3390/jof8090962. View